Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:
Zix Corporation (NASDAQ:ZIXI)’s shares picked up 9.97%, and closed at $4.30.
Zix Corporation (ZIXI), and Cisco, have reached an OEM relationship for the development and distribution of improved email encryption solutions. The partnership will focus on two solutions in 2015 – an enhancement of the Cisco IronPort Encryption Appliance (IEA) and a new solution that integrates proven components of Cisco® and Zix® technology. Both solutions will be distributed by Cisco.
In partnering with ZixCorp, Cisco provides existing IEA customers with a solution that allows them to extend the life of their IEA implementations, and strengthens the Cisco security portfolio with new, easy-to-use email encryption from ZixCorp.
The updated version of Cisco IEA will comprise new hardware in addition to software patches to protect against the latest security threats. Encryption capabilities, reporting and end user interaction with Cisco IEA will remain the same, so customers will have a seamless upgrade path. The updated version of Cisco IEA will be accessible in May 2015.
“The new partnership with Cisco offers IEA customers an extended email encryption product with all the same features and user look and feel as they have recently. It also enables the Cisco channels to distribute a new combined solution that we believe will be attractive to high-end, enterprise customers,” said Rick Spurr, chief executive officer of ZixCorp. “We appreciate Cisco recognizing the competitive advantages of our combined solutions, and we look forward to a mutually beneficial relationship that fosters innovation for customers.”
ZixCorp is a leader in email data protection. ZixCorp offers industry-leading email encryption, a unique email DLP solution and an innovative email BYOD solution to meet your corporation’s data protection and compliance needs. ZixCorp is trusted by the nation’s most influential institutions in healthcare, finance and government for easy to use secure email solutions.
Synta Pharmaceuticals Corp (NASDAQ:SNTA), raised 9.88%, and closed at $2.67.
Synta Pharmaceuticals Corp. (SNTA), declared that it will report its fourth quarter and year-end 2014 financial results on March 12, 2015, before market open. Following the declaration, administration will host a conference call and webcast at 8:30 a.m. ET that morning to talk about the fourth quarter results and provide operational updates.
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical corporation focused on research, development and commercialization of novel oncology medicines that change cancer patients’ lives. Synta’s lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is presently being evaluated in several clinical trials counting the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer.
Celladon Corp (NASDAQ:CLDN), enhanced 9.29%, and closed at $21.46, hitting new 52-week high of $22.90. The company holds the book value per share of 3.95, whereas cash per share is 4.08. Price to book value is estimated to be 5.43. Analysts mean recommendation for the stock is said to be 1.30 (where 1=Buy, 5=sale).
Celladon Corporation, a clinical-stage biotechnology corporation, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases.
Nanosphere, Inc (NASDAQ:NSPH), enhanced 9.20%, and closed at $0.273.
Nanosphere, Inc. (NSPH), a corporation enhancing medicine through targeted molecular diagnostics, declared that it will conduct a special meeting of stockholders on Tuesday, April 7, 2015. At the special meeting, stockholders will be asked to approve amendments to Nanosphere’s charter to raise the authorized shares of its ordinary stock from 150 million to 250 million shares, and to effect a reverse stock split of its issued and outstanding ordinary stock with a ratio in a range of between 15-to-1 and 25-to-1 for the purpose of regaining compliance with the $1 minimum bid price requirement of the NASDAQ Capital Market. The board of directors will determine the exact ratio of the reverse stock split within such range, assuming stockholders approve the reverse stock split at the special meeting. Nanosphere’s board of directors has fixed a record date of February 26, 2015 for the special meeting. All stockholders of record as of the close of business on February 26, 2015 shall be entitled to notice of and to vote at the special meeting.
In connection with the special meeting of stockholders, Nanosphere has filed with the Securities and Exchange Commission a definitive proxy statement describing the charter amendments that will be mailed to stockholders on or about Friday, March 6, 2015 to solicit proxies in support of the charter amendments. Nanosphere has engaged MacKenzie Partners, Inc. to serve as its proxy solicitor for the special meeting of stockholder.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Corporation’s versatile technology platform, the Verigene (R) System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test.
